Cardinal Health entered this earnings week on a strong run, with the stock already up over the past quarter and edging another 1.3% higher to about US$240 by the close. The market reaction was positive but restrained for a distributor that just printed adjusted free cash flow of US$5.0b and full year revenue of US$254b. That gap between a modest price move and very large cash generation is the real story for you as a shareholder.

Is Cardinal Health a rare case where a rich P/E and heavy debt still sit beside a genuine valuation gap, or is the stock priced this way for a reason? Compare the market price with the DCF work already done in the valuation analysis for Cardinal Health.

FY 2026 Earnings Summary

• Revenue (FY 2026 vs. FY 2025 TTM): US$254.25b vs. US$222.58b (TTM increase of about 14%)
• Net Income (Excl. Extra Items, FY 2026 TTM vs. FY 2025 TTM): US$1.71b vs. US$1.56b (TTM increase of about 10%)
• Basic EPS (FY 2026 TTM vs. FY 2025 TTM): US$7.26 vs. US$6.48 (TTM increase of about 12%)
• Net Profit Margin (FY 2026 TTM vs. FY 2025 TTM): 0.7% vs. 0.7% (TTM margin broadly stable; the latest year was affected by a US$682.0m one off loss)

Prefer clear visuals instead of another wall of earnings tables and footnotes? See Cardinal Health's full financial picture, including an at a glance view of its valuation and cash generation, in the interactive company report for Cardinal Health.

Cardinal Health bull case hinges on cash and mix

Bulls argue Cardinal Health is evolving into critical healthcare infrastructure with a richer specialty and home care mix that supports strong EPS leverage. FY26 numbers give that story some backing. Revenue reached US$254.25b and adjusted free cash flow was US$5.0b, which helped fund US$1.35b of buybacks and a US$649m spend on automation and supply chain tech. Management is leaning into Specialty and at Home Solutions, with Solaris and the Strive and AdaptHealth deals expected to feed the higher margin growth engines that already helped push EPS to US$10.95 on a baseline. Guidance for Pharma & Specialty and the three growth businesses points to faster profit growth than revenue, which fits the mix shift thesis. The key milestone hit here is that specialty and home care are now material contributors, not just slide deck concepts.

Bear case tests reliance on one offs and GMPD

Bears focus on rich expectations, quality and one off support for EPS. FY26 gives them some ammunition. EPS benefited from a US$0.31 IEEPA tariff refund in Q4 and GMPD profit guidance explicitly relies on tariff tailwinds to offset commodity and fuel costs. Management still calls GMPD a work in progress, and profitability is expected to be back weighted to the second half. Recent Class II levothyroxine recalls at an affiliated distributor keep the quality control risk front and center just as regulators are watching drug supply closely. The reliance on ongoing acquisitions and tuck ins to hit double digit specialty and at home profit growth also keeps execution risk high. The stock only moved about 1.3% on the print, which suggests investors are treating these one offs and GMPD uncertainty as real constraints on the story.

After tariff refunds, recalls and acquisition reliance, are these just surface issues or early signs of deeper structural fragility? Review the risk analysis for Cardinal Health which shows 2 important warning signs.

Take Control of Your Next Move

If Cardinal Health's mix of large cash generation, acquisitions and tariff related moving parts has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and spot an entry that fits your plan. Once you own it, keep your decisions focused with the Portfolio Command Center that cuts through noise to surface only key developments. For long term context, tap into investor sentiment and debate through the Community so you are not assessing Cardinal Health in isolation. By spotting potential catalysts and risks early, you give yourself a better chance of staying a step ahead of the broader market.

Seeking Alternatives Beyond Cardinal Health

Fresh stock ideas can move from quiet to flying once momentum builds and prices re-rate. Scan these under the radar lists before the crowd catches on and consider them while they are still early in their development.

• Spot potential breakout income plays that combine dependable cash generation with higher yields using a curated set of 8 dividend fortresses, while they still sit under the wider market's radar.
• Hunt for fast growing, cash backed opportunities in a carefully filtered 20 high quality undiscovered gems before stronger momentum builds and ideal entry ranges change.
• Zero in on financially disciplined companies through the hand picked list of solid balance sheet and fundamentals stocks (50 results) and review them before other investors respond to balance sheet strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.